Several new technologies and medications have been introduced for the treatment and prevention of cardiovascular (CV) disease over the past recent years. Despite this, the high incidence of ischemic events is still a major concern in modern medicine and is responsible for a large number of hospitalizations and deaths worldwide. Antiplatelet therapy is key to reducing ischemic events amongst patients with CV disease, but is inevitably associated with increased bleeding. A better understanding of the prognostic implications associated with bleeding, together with the reduced thrombogenicity of stent platforms and devices, have led to a substantial evolution in antiplatelet treatment regimens over the past decades. Numerous studies have been conducted to better stratify patients with CV disease according to their ischemic and bleeding risks and to then implement antithrombotic regimens accordingly. Evidence from this research has led to the development of several antithrombotic treatment options, as recommended by recent Guidelines.
- Strategies for prevention and management of bleeding among patients with cardiovascular disease
- Tailoring antiplatelet therapy in patients undergoing PCI: current evidence and practical recommendations
Dr. Domenico D'Amario and Dr. Mattia Galli
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention
Long-term Antithrombotic Therapy in Secondary Prevention in Patients with Atherosclerotic Cardiovascular Disease
P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-term Secondary Prevention Post-PCI
Antithrombotic Therapy for Patients Undergoing Drug-coated Balloon PCI: State of the Art and Future Directions
Cortese B et al.
Dual Antiplatelet Therapy in Elderly Patients undergoing Percutaneous Coronary Intervention
Alberto Monello, Cosmo Godino
Reversal of Platelet Inhibition in Patients Receiving Ticagrelor
Piotr Adamski, Jacek Kubica